MMRGlobal Retains Counsel in Australia and Issues Patent Update

LOS ANGELES, CA--(Marketwired - Jun 3, 2013) - MyMedicalRecords, Inc. ("MMR"), a wholly owned subsidiary of MMRGlobal, Inc. (OTCQB: MMRF), today announced that it has retained the legal firm of Rockwell Olivier to represent the Company in Australia. Rockwell Olivier will join MMRGlobal CEO Robert H. Lorsch in July for licensing meetings in Australia. The firm will also represent MMR in respect to the impasse concerning the possible exploitation of the Company's MyMedicalRecords health IT Patents and Intellectual Property by NEHTA and others. Rockwell Olivier is a full service law firm with specialties in patent and trademark law. The firm has more than 130 employees including 24 principals and 50 other associates. Rockwell Olivier is headquartered in offices in Sydney and also maintains offices in Perth, Melbourne, visiting offices in PNG, Fiji, Vanuatu and a representative office in Singapore with affiliate relationships in more than 15 countries across the Asia Pacific Region. It had recently been brought to the Company's attention that government bodies in Australia, through the National E-Health Transition Authority (NEHTA), may have exploited the MMR patents (including Australian patent numbers 2006202057 and 2008202401) and other Intellectual Property (collectively, the "MMRIP") issued to MyMedicalRecords.com, Inc. NEHTA has reportedly spent an estimated one billion Australian dollars on an electronic Personal Health Records program which is the subject of the potential exploitation of the MMRIP.

MMR is also updating shareholders on the status of patent litigation domestically and licensing activities overseas. On January 31st, MyMedicalRecords, Inc. announced the filing of a complaint for patent infringement against Walgreen Co. The complaint alleges that Walgreens is infringing on MMR's Personal Health Records patent, specifically U.S. Patent No. 8,301,466, and as a result, MMR is seeking monetary damages as well as a permanent injunction. As stated in the complaint, Walgreens is the nation's largest drugstore chain with fiscal 2012 sales of $72 billion, operating 8061 drugstores and providing services to over 6 million customers. The complaint was filed in the United States District Court for the Central District of California, case number CV 13-00631, on January 29, 2013 and is available on the court's website http://www.pacer.gov/. The litigation is ongoing.

On February 12, 2013, MyMedicalRecords, Inc. announced the filing of a complaint for patent infringement against WebMD Health Corp. and its wholly owned subsidiary, WebMD Health Services Group, Inc. ("WebMD"). The complaint alleges that WebMD is infringing on MMR's Personal Health Records patents including U.S. Patent No. 8,301,466, and as a result, MMR is seeking monetary damages as well as a permanent injunction. The complaint was filed in the United States District Court for the Central District of California, case number CV 13-00979 (CAS/JCx), on February11, 2013, and is available on the court's website http://www.pacer.gov/. The parties have spent the last three months in continued talks as discussed in the Company's April 30th social media post at https://www.facebook.com/MMRGlobal?ref=hl. Accordingly, the Company expects to further update shareholders on the status of litigation by June 6th due to court imposed deadlines which the Company plans on meeting.

On April 11, 2013, MMR also announced the filing of a complaint for patent infringement against Quest Diagnostics, Inc. alleging that Quest is infringing on MMR's Personal Health Records patent, specifically, U.S. Patent No. 8,301,466, and as a result, MMR is seeking monetary damages as well as a permanent injunction. The complaint was filed in the United States District Court for the Central District of California, case number CV-13-2538-CBM (MNx), on April 10, 2013 and is available on the court's website http://www.pacer.gov/. As stated in the complaint, pursuant to its public records and statements, Quest is "the world's leading provider of diagnostic testing services with a medical and scientific staff of approximately 900 MDs and PhDs, an extensive network of convenient patient locations and laboratories and a range of complementary diagnostic products." According to the complaint, Quest offers a product known as Gazelle, a mobile health application that is a PHR. Gazelle allows a customer to receive and store through his or her cell phone medical information, including personal medical records amongst other things. It is still very early in the litigation, however, the two companies are in communication.

Lastly, on May 20, 2013, MMR announced the filing of a complaint for patent infringement against Jardogs LLC, a subsidiary of Allscripts. The complaint states that Jardogs provides health information services to consumers and healthcare providers and is infringing on MMR's Personal Health Records patents including U.S. Patent No. 8,301,466. According to the complaint, Jardogs provides a product called FollowMyHealth™ Universal Health Record, which it describes as the "next generation patient portal, combining patient-provider communication with a patient managed personal health record." The complaint alleges that Jardogs, while infringing on MMR's patent, also has induced others including Allscripts, distributors, agents, resellers and users to infringe one or more claims of the patent. MMR is seeking monetary damages as well as a permanent injunction. The complaint was filed in the United States District Court for the Central District of California, case number CV: 13-3560, on May 16, 2013, and is available on the court's website http://www.pacer.gov/.

MMR is a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions, and MMRPro document management and imaging systems for healthcare professionals. MMR currently has seven U.S. Health IT patents: U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; and 8,321,240. The MMR Patent Portfolio also includes additional applications and continuation applications with nearly 400 claims. The patents involve inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. MMR also has been granted patents and has other pending applications in countries of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, South Korea, Israel, and European nations.

On February 19, 2013, MMR announced that it has been brought to the Company's attention that vendors providing services to the Ministry of Health in Singapore appeared to be infringing on patents (including Singapore patent number 200801954) and other Intellectual Property issued to MyMedicalRecords, Inc. The Company has been advised that personally-controlled health records, or Personal Health Records, are included in programs for the Ministry of Health, the Health Promotion Board, the Health Sciences Authority and numerous other organizations in Singapore, which the Company believes is clearly part of MMR's inventions that led to its MyMedicalRecords patents. The Company has spoken with vendors and others in Singapore and is optimistic that as a result of its patents it can find licensees in the region to offer its IP.

The Company also recently announced relationships with representatives in the Middle East and potential licensees in Japan where the Company believes recent patent awards represent a significant opportunity at this time.

About MMRGlobalMMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.

Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property licenses, property enforcement actions, infringement claims or litigation, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation in the U.S. and internationally; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry both in the U.S. and internationally; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.